| pubmed-article:8270987 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8270987 | lifeskim:mentions | umls-concept:C0337810 | lld:lifeskim |
| pubmed-article:8270987 | lifeskim:mentions | umls-concept:C1336527 | lld:lifeskim |
| pubmed-article:8270987 | lifeskim:mentions | umls-concept:C0002475 | lld:lifeskim |
| pubmed-article:8270987 | lifeskim:mentions | umls-concept:C0021735 | lld:lifeskim |
| pubmed-article:8270987 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:8270987 | lifeskim:mentions | umls-concept:C1274040 | lld:lifeskim |
| pubmed-article:8270987 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:8270987 | lifeskim:mentions | umls-concept:C0439743 | lld:lifeskim |
| pubmed-article:8270987 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:8270987 | pubmed:dateCreated | 1994-1-31 | lld:pubmed |
| pubmed-article:8270987 | pubmed:abstractText | Interferons have shown a definite activity in the intravesical treatment of residual papillary bladder cancer or carcinoma in situ (CIS). The purpose of the present study was to investigate the efficacy of interferon alfa-2b (IFN) as prophylactic treatment of superficial bladder cancer. | lld:pubmed |
| pubmed-article:8270987 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8270987 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8270987 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8270987 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8270987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8270987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8270987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8270987 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8270987 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8270987 | pubmed:month | Jan | lld:pubmed |
| pubmed-article:8270987 | pubmed:issn | 0732-183X | lld:pubmed |
| pubmed-article:8270987 | pubmed:author | pubmed-author:BoccardiLL | lld:pubmed |
| pubmed-article:8270987 | pubmed:author | pubmed-author:MartoranaGG | lld:pubmed |
| pubmed-article:8270987 | pubmed:author | pubmed-author:CannataDD | lld:pubmed |
| pubmed-article:8270987 | pubmed:author | pubmed-author:DecensiAA | lld:pubmed |
| pubmed-article:8270987 | pubmed:author | pubmed-author:CurottoAA | lld:pubmed |
| pubmed-article:8270987 | pubmed:author | pubmed-author:CanobbioLL | lld:pubmed |
| pubmed-article:8270987 | pubmed:author | pubmed-author:RubagottiAA | lld:pubmed |
| pubmed-article:8270987 | pubmed:author | pubmed-author:GuarneriDD | lld:pubmed |
| pubmed-article:8270987 | pubmed:author | pubmed-author:SelvaggiFF | lld:pubmed |
| pubmed-article:8270987 | pubmed:author | pubmed-author:PegoraroCC | lld:pubmed |
| pubmed-article:8270987 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8270987 | pubmed:volume | 12 | lld:pubmed |
| pubmed-article:8270987 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8270987 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:8270987 | pubmed:pagination | 7-13 | lld:pubmed |
| pubmed-article:8270987 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:meshHeading | pubmed-meshheading:8270987-... | lld:pubmed |
| pubmed-article:8270987 | pubmed:year | 1994 | lld:pubmed |
| pubmed-article:8270987 | pubmed:articleTitle | Prophylaxis of superficial bladder cancer with mitomycin or interferon alfa-2b: results of a multicentric Italian study. | lld:pubmed |
| pubmed-article:8270987 | pubmed:affiliation | Department of Medical Oncology II, National Institute for Cancer Research, Genova, Italy. | lld:pubmed |
| pubmed-article:8270987 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8270987 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:8270987 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:8270987 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:8270987 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:8270987 | lld:pubmed |
